Erik Emerson was named Chief Executive Officer of Glucotrack, Inc. As of November 6, 2026, Glucotrack, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 15, 2026 to September 18, 2026, naming 2 appointments and 1 departure (Form 8-K, July 15, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Glucotrack, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Glucotrack, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-15 to 2026-09-18. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Glucotrack, Inc. files it.
Also on the record for Glucotrack, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 2, 2026 | Stake report, Schedule 13G, by White Lion Capital LLC | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Ikarian Capital, LLC | 4.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Glucotrack, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Glucotrack, Inc. and the records around it.
Glucotrack, Inc. elsewhere on the record
Companies that share a holder
- White Lion Capital LLC also filed stake reports on 4 other companies: Akari Therapeutics Plc (Aug 2026), Actelis Networks, Inc. (Jul 2026), CID Holdco, Inc. (Jun 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), Galera Therapeutics, Inc. (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Glucotrack, Inc.
Get an email when Glucotrack, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Glucotrack, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Glucotrack, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Glucotrack, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-18 | Out | 8-K, 2026-09-18 | |||
| 2026-07-15 | In | 8-K, 2026-07-15 | |||
| 2026-07-15 | In | Chief Executive Officer | 8-K, 2026-07-15 |
Who leads Glucotrack, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Erik Emerson, appointed (filed 2026-07-15).
New leaders reset buying decisions — get the Full Report on Glucotrack, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Glucotrack, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Glucotrack, Inc.Every change, in the filing's words
Departing: Paul V. Goode
On September 14, 2026, Paul V. Goode notified the Board of Directors of Glucotrack, Inc. (the "Company") of his resignation from the Board, effective immediately.
Appointed: Erik Emerson
On July 9, 2026, the Acquiror Board expanded the size of the Board from five (5) members to six (6) members, effective upon the Closing, and appointed Erik Emerson to fill the vacancy created by such expansion, effective upon the Closing.
Appointed: Erik Emerson, Chief Executive Officer
Mr. Emerson was appointed Chief Executive Officer of Lokahi Therapeutics Inc. in December 2025.
- Mr. Emerson previously served as Chief Executive Officer of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) from September 2023 to December 2025, and as a director of the company from October 2024 to January 2026.
- From August 2022 to October 2023, Mr. Emerson has served as Chief Commercial Officer of Odyssey Neuropharma, Inc., where he lead commercial strategy, forecasting, branding, marketing, and financing efforts for a Phase II asset in evaluation for the treatment of mild traumatic brain injury (concussion).
- He has also served as an advisory board member to NuGen Medical Devices from August 2022 to May 2023, and as a Partner at Pharmacense Consulting from May 2020 to October 2023.
- Mr. Emerson served as Chief Commercial Officer of Mezzion Pharmaceuticals, a Korean company establishing U.S. operations for the treatment of Single Ventricle Heart Disease following Fontan surgery, from February 2017 to January 2020.
- During an overlapping period, from February 2018 to November 2019, he served as Chief Commercial Officer and a board member of Adhera Therapeutics (previously known as Marina Biotech).
- Concurrently, from July 2017 to November 2019, he served as Executive Chairman and Chief Executive Officer of BioMauris LLC, a software entity he founded to track medicinal marijuana products from seed to sale, built on technology adapted from his prior venture, Symplmed.
Tools for this story
Each opens in a new tab, filled in for Glucotrack, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.